Key result
The automatic implantable cardioverter-defibrillator (AICD) resulted in two deaths and five complications requiring reoperation among 21 patients over a mean follow-up of 19 months.
Why the study?
Does the automatic implantable cardioverter-defibrillator (AICD) improve survival in patients with recurrent ventricular dysrhythmias?
Observational (n=21)
No
Does the automatic implantable cardioverter-defibrillator (AICD) improve survival in patients with recurrent ventricular dysrhythmias?
Early single-center experience with the AICD supports its use for improving survival in selected patients with recurrent ventricular dysrhythmias.
Answers are grounded in this paper and cite their sources.
Early AICD experience shows deaths and reoperations; leaves open net survival benefit in recurrent ventricular dysrhythmias.
The automatic implantable cardioverter-defibrillator (AICD) is a device of proven efficacy in life-threatening ventricular tachycardia and fibrillation. Initial experience with the AICD at the University of Miami consists of 21 patients with recurrent ventricular dysrhythmias for a total follow-up of 3-35 months (mean 19). There were two deaths in the series, one nonarrhythmic and one arrhythmic, at the fifth and tenth postoperative months respectively. There were five complications requiring reoperation in three patients. Pacemakers were required in four patients with the AICD and resulted in interesting observations. Our data concur with previously published reports of improved survival in selected patients.
No takes yet. Share an insight, caveat, or question.
Luceri et al. (1986) conducted an observational in Recurrent ventricular dysrhythmias (n=21). Automatic implantable cardioverter-defibrillator (AICD) was evaluated on Death. The automatic implantable cardioverter-defibrillator (AICD) resulted in two deaths and five complications requiring reoperation among 21 patients over a mean follow-up of 19 months.
Synapse has enriched 10 related papers. Consider them for comparative context: